Back

Watch Compare

Quince Therapeutics, Inc.

Data quality: 83%

QNCX

Nasdaq Manufacturing Chemicals

$0.12

▼ $0.06 (-32.66%)

Mkt Cap: 6.89 M

Price

$0.12

Mkt Cap

6.89 M

Day Range

$0.12 — $0.16

52-Week Range

$0.08 — $4.55

Volume

159,978,658

Open $0.13

50D / 200D Avg

$0.39

68.02% below

50D / 200D Avg

$1.70

92.76% below

Quick Summary

Key Takeaways

Debt/Equity of 0.00 — conservative balance sheet

Negative free cash flow of -38.98 M

Growth

Revenue Growth (5Y)

N/A

Revenue (1Y)N/A

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Quality

Return on Equity

-890.64%

Below sector avg (-53.41%)

ROIC-41.40%

Net MarginN/A

Op. MarginN/A

Safety

Debt / Equity

0.00

Below sector avg (0.31)

Current Ratio1.12

Interest CoverageN/A

Valuation

PE (TTM)

-0.12

Above sector avg (-1.48)

P/B Ratio6.50

EV/EBITDAN/A

Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)

Metric	Stock	Sector Median
P/E	-0.1	-1.5
P/B	6.5	1.6
ROE %	-890.6	-53.4
Net Margin %	—	-41.5
Rev Growth 5Y %	—	1.8
D/E	0.0	0.3

All Fundamental Metrics

Growth
Revenue Growth (1Y)	N/A	Revenue Growth (3Y)	N/A
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	N/A	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	N/A	Net Income (TTM)	-56.98 M
ROE	-890.64%	ROA	-50.18%
Gross Margin	N/A	Operating Margin	N/A
Net Margin	N/A	Free Cash Flow (TTM)	-38.98 M
ROIC	-41.40%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	0.00	Current Ratio	1.12
Interest Coverage	N/A	Asset Turnover	N/A
Working Capital	3.16 M	Tangible Book Value	-66.67 M
Dividends
Dividend Yield	N/A	Payout Ratio	N/A
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A
Valuation
P/E Ratio	-0.12	Forward P/E	N/A
P/B Ratio	6.50	P/S Ratio	N/A
PEG Ratio	N/A	Forward PEG	N/A
EV/EBITDA	N/A	Fwd EV/EBITDA	N/A
Forward P/S	N/A	Fwd Earnings Yield	N/A
FCF Yield	-565.88%
Market Cap	6.89 M	Enterprise Value	435,800.0
Per Share
EPS (Diluted TTM)	-1.20	Revenue / Share	N/A
FCF / Share	-0.70	OCF / Share	-0.69
EPS CAGR (1Y)	N/A	EPS CAGR (5Y)	N/A
EPS CAGR (10Y)	N/A
Efficiency
CapEx / Revenue	N/A	FCF Conversion	68.41%
SBC-Adj. FCF	-44.02 M	Growth Momentum	N/A

Income Statement

Annual, most recent first

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	—	—	—	—	—
Net Income	-56.83 M	-31.39 M	-51.66 M	-89.95 M	-76.85 M
EPS (Diluted)	-1.31	-0.84	-1.54	—	—
Gross Profit	—	—	—	—	—
Operating Income	-57.29 M	-34.62 M	-52.02 M	-90.32 M	-78.89 M
EBITDA	—	—	—	—	—
R&D Expenses	18.59 M	9.45 M	25.18 M	60.80 M	61.31 M
SG&A Expenses	—	—	—	—	—
D&A	186,000.0	322,000.0	204,000.0	344,000.0	332,000.0
Interest Expense	—	—	—	—	957,000.0
Income Tax	87,000.0	197,000.0	-284,000.0	—	0.0

Balance Sheet

Annual, most recent first

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Total Assets	114.48 M	167.90 M	103.91 M	133.23 M	189.47 M
Total Liabilities	84.33 M	82.82 M	3.32 M	14.64 M	17.20 M
Shareholders' Equity	30.15 M	85.08 M	100.59 M	118.59 M	172.26 M
Total Debt	14.32 M	13.43 M	—	—	—
Cash & Equivalents	40.80 M	75.10 M	90.20 M	106.80 M	133.80 M
Current Assets	44.04 M	77.44 M	93.75 M	111.67 M	137.86 M
Current Liabilities	7.28 M	9.57 M	3.07 M	14.22 M	17.00 M